NAIL FUNGUS DRUG EFFICACY BASED ON CLINICAL ENDPOINTS
This article was originally published in The Tan Sheet
Executive Summary
NAIL FUNGUS DRUG EFFICACY BASED ON CLINICAL ENDPOINTS, not a negative mycological culture, is accept- able, FDA's Dermatologic Drags Advisory Committee concurred at a Sept. 23 meeting. "I think we've got consensus here," said committee Chair Wilma Bergfeld, MD, Cleveland Clinic Foundation. "The basis of success is a cleared nail bed."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning